T1	PROC 47 102	Estudio de fase 3b/4 aleatorizado, abierto, enmascarado
T3	PROC 145 192	comparar la seguridad y la eficacia enmascarada
T4	LIVB 202 213	evaluadores
T5	CHEM 217 229	upadacitinib
T6	CHEM 239 248	dupilumab
#1	AnnotatorNotes T6	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	LIVB 252 261	pacientes
#2	AnnotatorNotes T7	C0030705; Patients; Patient or Disabled Group
T8	DISO 266 284	dermatitis atópica
#3	AnnotatorNotes T8	C0011615; Dermatitis, Atopic; Disease or Syndrome
T9	DISO 327 345	Dermatitis atópica
#4	AnnotatorNotes T9	C0011615; Dermatitis, Atopic; Disease or Syndrome
T10	DISO 367 373	Eczema
#5	AnnotatorNotes T10	C0013595; Eczema; Disease or Syndrome
T11	LIVB 403 412	Pacientes
#6	AnnotatorNotes T11	C0030705; Patients; Patient or Disabled Group
T12	Age 413 421	≥12 años
T13	Age 455 463	<65 años
T14	LIVB 468 475	Sujetos
#7	AnnotatorNotes T14	C0681850; Study Subject; Group
T15	DISO 480 490	DA crónica
T16	Duration 483 490	crónica
T17	DISO 497 505	síntomas
#8	AnnotatorNotes T17	C1457887; Symptoms; Sign or Symptom
T18	Duration 518 533	al menos 3 años
T19	ANAT 654 673	superficie corporal
T20	ANAT 675 677	SC
#9	AnnotatorNotes T20	C0456944; Coronary sinus structure; Body Part, Organ, or Organ Component | C1269893; Entire coronary sinus; Body Part, Organ, or Organ Component
T21	DISO 695 697	DA
T22	PROC 710 716	visita
T23	Frequency 736 743	semanal
T24	Frequency 767 773	diaria
T25	PROC 780 786	WP-NRS
T26	PROC 849 870	tratamiento sistémico
T27	PROC 967 988	tratamiento sistémico
T28	DISO 1004 1006	DA
T31	PROC 1070 1093	tratamientos sistémicos
T33	Contraindicated 1070 1093	tratamientos sistémicos
T34	CHEM 1179 1195	inhibidor de JAK
T35	Route 1196 1200	oral
T36	Route 1203 1209	tópico
T37	CHEM 1235 1247	upadacitinib
T38	CHEM 1249 1255	Rinvoq
T39	CHEM 1259 1270	tofacitinib
#10	AnnotatorNotes T39	C2930696; tofacitinib; Organic Chemical · Pharmacologic Substance
T40	CHEM 1272 1279	Xeljanz
T41	CHEM 1283 1294	ruxolitinib
#11	AnnotatorNotes T41	C2931926; ruxolitinib; Organic Chemical · Pharmacologic Substance
T42	CHEM 1296 1302	Jakafi
#12	AnnotatorNotes T42	C3247913; Jakafi; Organic Chemical · Pharmacologic Substance
T43	CHEM 1306 1314	Opzelura
T44	CHEM 1318 1329	baricitinib
#13	AnnotatorNotes T44	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T45	CHEM 1331 1339	Olumiant
T46	CHEM 1343 1354	peficitinib
T47	CHEM 1356 1362	Smyraf
T48	CHEM 1366 1377	abrocitinib
T49	CHEM 1379 1386	Cibinqo
T50	CHEM 1391 1401	filgotinib
#14	AnnotatorNotes T50	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T51	CHEM 1403 1411	Jyseleca
T52	CHEM 1437 1446	dupilumab
#15	AnnotatorNotes T52	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T53	CHEM 1448 1460	tralokinumab
T54	CHEM 1463 1475	lebrikizumab
T55	LIVB 112 123	evaluadores
T2	PROC 576 604	criterios de Hanifin y Rajka
T56	PROC 620 624	EASI
T29	Route 979 988	sistémico
T30	Route 861 870	sistémico
T32	Route 1083 1093	sistémicos
